{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:07:08Z","timestamp":1779228428363,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":122,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Human papillomavirus (HPV)-related diseases have risen in Japan since recommendations for the HPV vaccine were suspended in 2013. This study evaluated the public health benefit of extending the current 3-year nonavalent HPV (9vHPV) catch-up vaccination program for females 17\u201326 years of age to 6 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A dynamic transmission model calibrated to Japanese specific demographic and epidemiological data compared the impact of different 9vHPV vaccination scenarios on female and male HPV-related diseases over a 100-year time horizon. The base-case analysis compared the routine vaccination in combination with the current 3-year catch-up program for females 17\u201326 years of age from 2022 to 2025 (status quo) to the routine vaccination in combination with an extended 6-year program from 2022 to 2028 (6-year catch-up scenario) for Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HPV-related disease incidence with the 6-year catch-up scenario decreased further than the status quo over 100 years. Extending catch-up vaccinations from three to six years in combination with routine vaccination prevented an additional 413,454 HPV-related disease cases and 7,184 deaths for both sexes. Anogenital warts had the highest number of averted cases (361,020 cases) and males (229,867 cases) had more total HPV-related disease cases averted than females (183,586 cases).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Routine vaccination in combination with an extension of the catch-up HPV vaccination strategy for females 17\u201326 years of age from three to six years may expedite the decrease of morbidity and mortality due to HPV-related diseases in Japan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-025-25684-8","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T13:04:57Z","timestamp":1765026297000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The public health impact of extending the catch-up nonavalent human papillomavirus vaccination program to 2028 in Japan: a model-based study"],"prefix":"10.1186","volume":"26","author":[{"given":"Ibrahim","family":"Diakite","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Tobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuedan","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cody","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taizo","family":"Matsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"25684_CR1","unstructured":"Centers for Disease Control and Prevention. HPV Vaccine: Reasons to get vaccinated 2021 [updated August 16, 2023. Available from: https:\/\/www.cdc.gov\/hpv\/vaccines\/reasons-to-get.html"},{"issue":"48","key":"25684_CR2","doi-asserted-by":"publisher","first-page":"7147","DOI":"10.1016\/j.vaccine.2023.10.024","volume":"41","author":"M Terada","year":"2023","unstructured":"Terada M, Shimazu T, Saito J, Odawara M, Otsuki A, Yaguchi-Saito A, et al. Age, gender and socioeconomic disparities in human papillomavirus (HPV) awareness and knowledge among Japanese adults after a 7-year suspension of proactive recommendation for the HPV vaccine: a nationally representative cross-sectional survey. Vaccine. 2023;41(48):7147\u201358.","journal-title":"Vaccine"},{"key":"25684_CR3","unstructured":"World Health Organization. Human Papillomavirus (HPV) and Cancer 2023 [Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/human-papilloma-virus-and-cancer"},{"issue":"4","key":"25684_CR4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jiph.2023.02.014","volume":"16","author":"AAA Oyouni","year":"2023","unstructured":"Oyouni AAA. Human papillomavirus in cancer: infection, disease transmission, and progress in vaccines. J Infect Public Health. 2023;16(4):626\u201331.","journal-title":"J Infect Public Health"},{"key":"25684_CR5","unstructured":"Bruni LAG, Serrano B, Mena M, Collado JJ, G\u00f3mez D, Mu\u00f1oz J, Bosch FX, de Sanjos\u00e9 S, ICO\/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Japan: HPV Information Centre; 2023. Available from: https:\/\/hpvcentre.net\/datastatistics.php updated 10 Mar 2023"},{"issue":"6","key":"25684_CR6","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1158\/0008-5472.CAN-18-3109","volume":"79","author":"A Yagi","year":"2019","unstructured":"Yagi A, Ueda Y, Kakuda M, Tanaka Y, Ikeda S, Matsuzaki S, et al. Epidemiologic and clinical analysis of cervical cancer using data from the population-based Osaka Cancer Registry. Cancer Res. 2019;79(6):1252\u20139.","journal-title":"Cancer Res"},{"key":"25684_CR7","unstructured":"Bruni LAG, Serrano B, Mena M, Collado JJ, G\u00f3mez D, Mu\u00f1oz J, Bosch FX, de Sanjos\u00e9, S. ICO\/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World. Summary Report 2023 [Available from: https:\/\/hpvcentre.net\/datastatistics.php"},{"issue":"7","key":"25684_CR8","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1111\/cas.16167","volume":"115","author":"A Yagi","year":"2024","unstructured":"Yagi A, Ueda Y, Oka E, Nakagawa S, Kimura T, Shimoya K. Even though active recommendation for HPV vaccination has restarted, Japan\u2019s rates have not recovered. Cancer Sci. 2024;115(7):2410\u20136.","journal-title":"Cancer Sci"},{"key":"25684_CR9","unstructured":"World Health Organization. Safety of HPV vaccines: extract from report of GACVS meeting of June 7\u20138 2017 2017 [Available from: https:\/\/www.who.int\/groups\/global-advisory-committee-on-vaccine-safety\/topics\/human-papillomavirus-vaccines\/safety"},{"key":"25684_CR10","unstructured":"Centers for Disease Control and Prevention. HPV Vaccine Safety and Effectiveness Data 2024 [Available from: https:\/\/www.cdc.gov\/hpv\/hcp\/vaccination-considerations\/safety-and-effectiveness-data.html?CDC_AAref_Val=https:\/\/www.cdc.gov\/hpv\/hcp\/vaccine-safety-data.html"},{"issue":"10451","key":"25684_CR11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0140-6736(24)01097-3","volume":"404","author":"F Wei","year":"2024","unstructured":"Wei F, Georges D, Man I, Baussano I, Clifford GM. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet (London England). 2024;404(10451):435\u201344.","journal-title":"Lancet (London England)"},{"key":"25684_CR12","unstructured":"National Cancer Institute. Human Papillomavirus (HPV) Vaccines 2021 [Available from: https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/risk\/infectious-agents\/hpv-vaccine-fact-sheet#r1"},{"issue":"12","key":"25684_CR13","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1080\/14760584.2022.2129615","volume":"21","author":"WV Wang","year":"2022","unstructured":"Wang WV, Kothari S, Skufca J, Giuliano AR, Sundstrom K, Nygard M, et al. Real-world impact and effectiveness of the quadrivalent HPV vaccine: an updated systematic literature review. Expert Rev Vaccines. 2022;21(12):1799\u2013817.","journal-title":"Expert Rev Vaccines"},{"issue":"10197","key":"25684_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","volume":"394","author":"M Drolet","year":"2019","unstructured":"Drolet M, Benard E, Perez N, Brisson M, Group HPVVIS. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497\u2013509.","journal-title":"Lancet"},{"key":"25684_CR15","volume":"44","author":"MR Palmer","year":"2024","unstructured":"Palmer MR, Saito E, Katanoda K, Sakamoto H, Hocking JS, Brotherton JML, et al. The impact of alternate HPV vaccination and cervical screening strategies in Japan: a cost-effectiveness analysis. The Lancet Regional Health. 2024;44:101018.","journal-title":"The Lancet Regional Health"},{"issue":"1","key":"25684_CR16","doi-asserted-by":"publisher","first-page":"15945","DOI":"10.1038\/s41598-020-73106-z","volume":"10","author":"A Yagi","year":"2020","unstructured":"Yagi A, Ueda Y, Nakagawa S, Ikeda S, Tanaka Y, Sekine M, et al. Potential for cervical cancer incidence and death resulting from Japan\u2019s current policy of prolonged suspension of its governmental recommendation of the HPV vaccine. Sci Rep. 2020;10(1):15945.","journal-title":"Sci Rep"},{"issue":"12","key":"25684_CR17","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(18)30573-4","volume":"19","author":"Y Ueda","year":"2018","unstructured":"Ueda Y, Yagi A, Ikeda S, Enomoto T, Kimura T. Beyond resumption of the Japanese government\u2019s recommendation of the HPV vaccine. Lancet Oncol. 2018;19(12):1563\u20134.","journal-title":"Lancet Oncol"},{"issue":"9987","key":"25684_CR18","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1016\/S0140-6736(15)61152-7","volume":"385","author":"SJ Hanley","year":"2015","unstructured":"Hanley SJ, Yoshioka E, Ito Y, Kishi R. HPV vaccination crisis in Japan. Lancet (London England). 2015;385(9987):2571.","journal-title":"Lancet (London England)"},{"issue":"4","key":"25684_CR19","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1016\/S2468-2667(20)30010-4","volume":"5","author":"KT Simms","year":"2020","unstructured":"Simms KT, Hanley SJB, Smith MA, Keane A, Canfell K. Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study. Lancet Public Health. 2020;5(4):e223-34.","journal-title":"Lancet Public Health"},{"key":"25684_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12052004","author":"M Lelliott","year":"2023","unstructured":"Lelliott M, Sahker E, Poudyal H. A review of parental vaccine hesitancy for Human Papillomavirus in Japan. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12052004.","journal-title":"J Clin Med"},{"key":"25684_CR21","volume":"18","author":"A Yagi","year":"2022","unstructured":"Yagi A, Ueda Y, Ikeda S, Miyagi E, Sekine M, Enomoto T, et al. The looming health hazard: a wave of HPV-related cancers in Japan is becoming a reality due to the continued suspension of the governmental recommendation of HPV vaccine. The Lancet Regional Health. 2022;18:100327.","journal-title":"The Lancet Regional Health"},{"issue":"1","key":"25684_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12879-020-05632-0","volume":"21","author":"P Cody","year":"2021","unstructured":"Cody P, Tobe K, Abe M, Elbasha EH. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study. BMC Infect Dis. 2021;21(1):11.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"25684_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S1470-2045(22)00002-X","volume":"23","author":"R Haruyama","year":"2022","unstructured":"Haruyama R, Obara H, Fujita N. Japan resumes active recommendations of HPV vaccine after 8.5 years of suspension. Lancet Oncol. 2022;23(2):197\u20138.","journal-title":"Lancet Oncol"},{"key":"25684_CR24","unstructured":"Ministry of Health, Labor, and Welfare. Regarding future measures for routine vaccinations related to human papillomavirus infections. 2021 [Available from: https:\/\/www.mhlw.go.jp\/content\/000875155.pdf"},{"key":"25684_CR25","unstructured":"Ministry of Health, Labor, and, Welfare. Regarding implementation of HPV vaccine catch-up vaccination, etc . 2022 [Available from: https:\/\/www.mhlw.go.jp\/content\/000915791.pdf"},{"key":"25684_CR26","unstructured":"Ministry of Health LaW. About catch-up vaccination of human papillomavirus (HPV) vaccine [Available from: https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/kenkou\/hpv_catch-up-vaccination.html"},{"issue":"1","key":"25684_CR27","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1080\/13696998.2023.2282912","volume":"26","author":"C Palmer","year":"2023","unstructured":"Palmer C, Tobe K, Negishi Y, You X, Chen YT, Abe M. Health impact and cost effectiveness of implementing gender-neutral HPV vaccination in Japan. J Med Econ. 2023;26(1):1546\u201354.","journal-title":"J Med Econ"},{"key":"25684_CR28","unstructured":"Pneumococcal Vaccination Guidelines. for Adults 65 Years of Age and Older 2024 [Available from: https:\/\/jsvac.jp\/pdfs\/20240906.pdf"},{"issue":"2","key":"25684_CR29","doi-asserted-by":"publisher","first-page":"2258569","DOI":"10.1080\/21645515.2023.2258569","volume":"19","author":"I Diakite","year":"2023","unstructured":"Diakite I, Kyle J, Situ S, Bai P, Zhang X, Wang W, et al. Public health impact of 2-, 4-, and 9-valent HPV vaccination in females on cervical and noncervical diseases in men and women under different coverage scenarios in China: a simulation study. Hum Vaccin Immunother. 2023;19(2):2258569.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"25684_CR30","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1080\/13696998.2023.2250194","volume":"26","author":"I Diakite","year":"2023","unstructured":"Diakite I, Nguyen S, Sabale U, Pavelyev A, Saxena K, Tajik AA, et al. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases. J Med Econ. 2023;26(1):1085\u201398.","journal-title":"J Med Econ"},{"key":"25684_CR31","unstructured":"World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem Geneva: World Health Organization2020 [Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240014107"},{"issue":"7","key":"25684_CR32","doi-asserted-by":"publisher","first-page":"e2325212","DOI":"10.1001\/jamanetworkopen.2023.25212","volume":"6","author":"A Miyawaki","year":"2023","unstructured":"Miyawaki A, Kitajima K, Iwata A, Sato D, Tsugawa Y. Antibiotic prescription for outpatients with COVID-19 in primary care settings in Japan. JAMA Netw Open. 2023;6(7):e2325212.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"25684_CR33","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/cas.16055","volume":"115","author":"A Yagi","year":"2024","unstructured":"Yagi A, Nakagawa S, Ueda Y, Oka E, Ikeda S, Kakuda M, et al. Effectiveness of catch-up and routine program of the 9-valent vaccine on cervical cancer risk reduction in Japan. Cancer Sci. 2024;115(3):916\u201325.","journal-title":"Cancer Sci"},{"key":"25684_CR34","unstructured":"Vaccine Japan. HPV (cervical cancer) vaccination rate data provided by M3 Research Institute 2025 [Available from: https:\/\/vaccine-japan.com\/"},{"issue":"7","key":"25684_CR35","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jama.298.7.743","volume":"298","author":"A Hildesheim","year":"2007","unstructured":"Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298(7):743\u201353.","journal-title":"JAMA"},{"issue":"2","key":"25684_CR36","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ajog.2016.02.021","volume":"215","author":"A Hildesheim","year":"2016","unstructured":"Hildesheim A, Gonzalez P, Kreimer AR, Wacholder S, Schussler J, Rodriguez AC, et al. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am J Obstet Gynecol. 2016;215(2):212. e1- e15.","journal-title":"Am J Obstet Gynecol"},{"issue":"RR\u201305","key":"25684_CR37","first-page":"1","volume":"63","author":"LE Markowitz","year":"2014","unstructured":"Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2014;63(RR\u201305):1\u201330.","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"25684_CR38","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1080\/21645515.2016.1172754","volume":"12","author":"Z Wangu","year":"2016","unstructured":"Wangu Z, Hsu KK. Impact of HPV vaccination on anogenital warts and respiratory papillomatosis. Hum Vaccin Immunother. 2016;12(6):1357\u201362.","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"25684_CR39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/OLQ.0000000000000948","volume":"46","author":"AE Yakely","year":"2019","unstructured":"Yakely AE, Avni-Singer L, Oliveira CR, Niccolai LM. Human papillomavirus vaccination and anogenital warts: a systematic review of impact and effectiveness in the united States. Sex Transm Dis. 2019;46(4):213\u201320.","journal-title":"Sex Transm Dis"},{"issue":"12","key":"25684_CR40","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/OLQ.0000000000000381","volume":"42","author":"WA Calo","year":"2015","unstructured":"Calo WA, Brewer NT. Trends in genital warts in the era of human papillomavirus vaccination. Sex Transm Dis. 2015;42(12):669\u201370.","journal-title":"Sex Transm Dis"},{"issue":"12","key":"25684_CR41","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/S1473-3099(21)00071-2","volume":"21","author":"EPF Chow","year":"2021","unstructured":"Chow EPF, Carter A, Vickers T, Fairley CK, McNulty A, Guy RJ, et al. Effect on genital warts in Australian female and heterosexual male individuals after introduction of the national human papillomavirus gender-neutral vaccination programme: an analysis of national sentinel surveillance data from 2004-18. Lancet Infect Dis. 2021;21(12):1747\u201356.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"25684_CR42","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/S1470-2045(22)00259-5","volume":"23","author":"M Sekine","year":"2022","unstructured":"Sekine M, Yamaguchi M, Kudo R, Hanley SJB, Ueda Y, Kurosawa M, et al. Problems with catch-up HPV vaccination after resumption of proactive recommendations. Lancet Oncol. 2022;23(8):972\u20133.","journal-title":"Lancet Oncol"},{"issue":"12","key":"25684_CR43","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1007\/s10147-023-02411-0","volume":"28","author":"S Nakagawa","year":"2023","unstructured":"Nakagawa S, Yagi A, Ueda Y, Ikeda S, Kakuda M, Hiramatsu K, et al. Intentions for catch-up HPV vaccination in japan: an internet survey. Int J Clin Oncol. 2023;28(12):1667\u201379.","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"25684_CR44","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41562-021-01122-8","volume":"5","author":"E Mathieu","year":"2021","unstructured":"Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021;5(7):947\u201353.","journal-title":"Nat Hum Behav"},{"issue":"12","key":"25684_CR45","doi-asserted-by":"publisher","first-page":"e41928","DOI":"10.2196\/41928","volume":"24","author":"R Kobayashi","year":"2022","unstructured":"Kobayashi R, Takedomi Y, Nakayama Y, Suda T, Uno T, Hashimoto T, et al. Evolution of public opinion on COVID-19 vaccination in japan: large-scale Twitter data analysis. J Med Internet Res. 2022;24(12):e41928.","journal-title":"J Med Internet Res"},{"issue":"1","key":"25684_CR46","doi-asserted-by":"publisher","first-page":"17762","DOI":"10.1038\/s41598-023-44942-6","volume":"13","author":"T Kayano","year":"2023","unstructured":"Kayano T, Ko Y, Otani K, Kobayashi T, Suzuki M, Nishiura H. Evaluating the COVID-19 vaccination program in Japan, 2021 using the counterfactual reproduction number. Sci Rep. 2023;13(1):17762.","journal-title":"Sci Rep"},{"issue":"7911","key":"25684_CR47","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/d41586-022-01385-9","volume":"605","author":"H Oshitani","year":"2022","unstructured":"Oshitani H. COVID lessons from Japan: the right messaging empowers citizens. Nature. 2022;605(7911):589.","journal-title":"Nature"},{"key":"25684_CR48","unstructured":"National Cancer Institute. Cervical Cancer Screening [updated May 17. 2024. Available from: https:\/\/www.cancer.gov\/types\/cervical\/screening"},{"key":"25684_CR49","unstructured":"Cancer registry and statistics. National Cancer Center. 2022 Cervical cancer screening. [Available from: https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/screening\/screening.html"},{"issue":"10","key":"25684_CR50","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1093\/jnci\/djab080","volume":"113","author":"SK Kjaer","year":"2021","unstructured":"Kjaer SK, Dehlendorff C, Belmonte F, Baandrup L. Real-world effectiveness of human papillomavirus vaccination against cervical cancer. J Natl Cancer Inst. 2021;113(10):1329\u201335.","journal-title":"J Natl Cancer Inst"},{"key":"25684_CR51","unstructured":"National Cancer Institute. HPV and, Cancer, [updated. May 9, 2025. Available from: https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/risk\/infectious-agents\/hpv-and-cancer#how-does-hpv-cause-cancer"},{"issue":"7","key":"25684_CR52","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1080\/21645515.2020.1852870","volume":"17","author":"V Daniels","year":"2021","unstructured":"Daniels V, Prabhu VS, Palmer C, Samant S, Kothari S, Roberts C, et al. Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States. Hum Vaccin Immunother. 2021;17(7):1943\u201351.","journal-title":"Hum Vaccin Immunother"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-25684-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-25684-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-25684-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T12:11:18Z","timestamp":1775563878000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12889-025-25684-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["25684"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-25684-8","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An established dynamic transmission model was adapted from previous 9vHPV modeling studies for Japan [\n                      \n                      ,\n                      \n                      ]. Baseline historical catch-up vaccination coverage were calculated with catch-up vaccination data for individuals with birth years between 1997 and 2005 from the Japan Medical Data Survey database (JAMDAS) [\n                      \n                      ]. Ethics review was not required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ibrahim Diakite, Xuedan You, Ya-Ting Chen, and Cody Palmer are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may hold stock in Merck & Co., Inc., Rahway, NJ, USA. Keisuke Tobe and Taizo Matsuki are employees of MSD K.K., Tokyo, Japan and may own stock and\/or hold stock options in Merck & Co., Inc., Rahway, NJ, USA.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1113"}}